RU 486/prostaglandin: considerations for appropriate use in low-resource settings

Law Med Health Care. Fall 1992;20(3):169-83. doi: 10.1111/j.1748-720x.1992.tb01185.x.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Abortifacient Agents, Steroidal* / adverse effects
  • Adult
  • Consumer Product Safety
  • Cultural Diversity
  • Developing Countries
  • Drug Approval
  • Drug Costs
  • Drug Synergism
  • Europe
  • Female
  • France
  • Health Services Accessibility
  • Humans
  • Information Dissemination
  • Internationality*
  • Maternal Mortality
  • Mifepristone* / adverse effects*
  • Patient Selection
  • Pregnancy
  • Pregnant Women
  • Prostaglandins E, Synthetic* / adverse effects
  • Risk Assessment
  • Social Control, Formal
  • United States
  • Vacuum Curettage / adverse effects
  • Vulnerable Populations

Substances

  • Abortifacient Agents, Steroidal
  • Prostaglandins E, Synthetic
  • Mifepristone